Wnt信号通路抑制剂调控肿瘤免疫微环境的机制研究
批准号:
81872895
项目类别:
面上项目
资助金额:
57.0 万元
负责人:
朱棣
依托单位:
学科分类:
H3505.抗肿瘤药物药理
结题年份:
2022
批准年份:
2018
项目状态:
已结题
项目参与者:
杨孟选、黄洵、夏莉、常汝略、王晓双、冯梅
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
结直肠癌是我国发病率第三位的癌症。Wnt/β-catenin信号通路异常活化是结直肠癌发生发展的重要原因,也是临床治疗的重要靶点。同时Wnt信号通路也参与调节肿瘤免疫微环境,可能影响免疫治疗的效果。申请人前期工作发现靶向β-catenin/BCL9的Wnt信号通路抑制剂(Science Translational Medicine,2012),并立足于之前在肿瘤微环境的经验(Nature Medicine,2015),已发现抑制β-catenin转录对于CD8+T细胞和Treg细胞肿瘤浸润有重要影响,同时调节趋化因子和细胞因子的表达。本项目将利用细胞、小鼠模型和临床标本,确认抑制Wnt信号通路对结直肠癌发生发展的重要性和机制;研究Wnt通路调控肿瘤免疫微环境的分子机制及干预方法;探讨Wnt信号抑制剂增强免疫治疗的效果。相关研究成果能够为肿瘤免疫治疗提供新的手段,为临床免疫联用提供理论基础。
英文摘要
Colorectal cancer is the third most prevalent cancer in China. The Wnt/β-catenin (β-cat) pathway plays a critical role in cancer initiation and progression and β-cat is an important target for cancer therapy. Recent studies also reported an emerging role of Wnt/β-cat in evading immune surveillance and inhibition of Wnt signaling activity could potential improve immuno-therapy outcome. In our previous study, we developed a hydro-carbon stapled peptide inhibitor targeting oncogenic Wnt activity by disrupting the interaction of β-cat with its co-activators B-cell lymphoma 9 (BCL9) and its homologue B-cell lymphoma 9-like (B9L). We further optimized the parental peptide and generated a new series of peptides. These newly generated stapled peptide inhibitors show strong anti-tumor efficacy and tolerability. In this study, we will take advantage of cellular models, animal models and patient samples. We will investigate the mechanism of inhibition of β-cat transcription activity in colorectal cancer development, to understand the molecular mechanism of targeting Wnt signaling pathway to modulate tumor immuno microenvironment and to explore synergy between Wnt inhibitor and checkpoint inhibitor in vivo. Outcome of this research will not only provide a new approach for cancer immuno-therapy but also scientific basis for clinical study. . The applicant of this grant proposal has accumulated extensive experience in this field and two of his selected first author publications are about tumor microenvironment research (Nature Medicine, 2015) and oncogenic Wnt inhibitor development (Science Translational Medicine, 2012). Based on our preliminary data, we found inhibition of β-catenin transcriptional activity promotes immune cell tumor infiltration and changes related chemokine/cytokine expression. In this grant proposal, we will further investigate the molecular mechanism of Wnt signaling pathway in regulating CD8+T cells and Treg cells tumor infiltration and uncover the chemokine and cytokine which could induce CD8+T cells and Treg cells migration. The purpose of this study is to provide the science basis for immunotherapy development targeting to β-cat/BCL9 as well as for future clinical trial design of combination therapy between Wnt inhibitor and checkpoint blocker antibodies.
结直肠癌是我国发病率第三位的癌症。Wnt/β-catenin信号通路异常活化是结直肠癌发生发展的重要原因,也是临床治疗的重要靶点。本项目聚焦Wnt信号通路参与调节肿瘤免疫微环境和免疫治疗开展了系统的研究。项目主要成果:1.阐明BCL9/β-catenin介导的肿瘤免疫耐药机理。2.开发靶向BCL9/β-catenin的新药分子。3.开发突破肿瘤免疫耐药的新疗法。这些工作验证了BCL9作为肿瘤免疫治疗新靶点,发现一系列新的肿瘤免疫治疗方法并开展转化,代表性工作发表在Cancer Discov.,Sci. Adv.,Signal Transduct Target Ther.等杂志,并完成成果转化。本项目发现的BCL9介导免疫耐药机制,验证了高应用性的免疫治疗新靶点,为新药开发和未来的临床试验提供理论基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer.
BCL9 调节 CD8~ T 细胞中的 CD226 和 CD96 检查点以改善癌症中的 PD-1 反应
DOI:10.1038/s41392-021-00730-0
发表时间:2021-08-20
期刊:Signal transduction and targeted therapy
影响因子:39.3
作者:Feng M;Wu Z;Zhou Y;Wei Z;Tian E;Mei S;Zhu Y;Liu C;He F;Li H;Xie C;Jin J;Dong J;Yang D;Yu K;Qian J;Lambrechts D;Wang MW;Zhu D
通讯作者:Zhu D
Inhibition of BCL9 Modulates the Cellular Landscape of Tumor-Associated Macrophages in the Tumor Immune Microenvironment of Colorectal Cancer.
抑制 BCL9 可调节结直肠癌肿瘤免疫微环境中肿瘤相关巨噬细胞的细胞景观
DOI:10.3389/fphar.2021.713331
发表时间:2021
期刊:Frontiers in pharmacology
影响因子:5.6
作者:Wei Z;Yang M;Feng M;Wu Z;Rosin-Arbesfeld R;Dong J;Zhu D
通讯作者:Zhu D
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment
IFNα 通过重塑肝细胞癌微环境中的葡萄糖代谢来增强抗 PD-1 功效
DOI:--
发表时间:2022
期刊:Cancer Discovery
影响因子:28.2
作者:Bo Hu;Mincheng Yu;Xiaolu Ma;Jialei Sun;Chenglong Liu;Chunyan Wang;Suiyi Wu;Peiyao Fu;Zhen Yang;Yungang He;Yuanyuan Zhu;Cheng Huang;Xinrong Yang;Yinghong Shi;Shuangjian Qiu;Huichuan Sun;Andrew X. Zhu;Jian Zhou;Yang Xu;Di Zhu;Jia Fan
通讯作者:Jia Fan
DOI:10.1186/s13046-022-02289-2
发表时间:2022-04-23
期刊:Journal of experimental & clinical cancer research : CR
影响因子:--
作者:
通讯作者:
T-cell-based immunotherapy in colorectal cancer
基于 T 细胞的结直肠癌免疫疗法
DOI:10.1016/j.canlet.2020.10.040
发表时间:2021-02-01
期刊:CANCER LETTERS
影响因子:9.7
作者:Feng, Mei;Zhao, Zhongwei;Zhu, Di
通讯作者:Zhu, Di
BCL9调控T细胞克隆扩增和促进CD8+T细胞杀伤机制研究
- 批准号:--
- 项目类别:面上项目
- 资助金额:52万元
- 批准年份:2022
- 负责人:朱棣
- 依托单位:
BCL9/9L调节T细胞的肿瘤浸润改善PD-1治疗耐药的研究
- 批准号:--
- 项目类别:面上项目
- 资助金额:55万元
- 批准年份:2020
- 负责人:朱棣
- 依托单位:
国内基金
海外基金















{{item.name}}会员


